Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
Addictive Behaviors|July 4, 2020
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adultsAngela M Haeny, LaTrice Montgomery, A Kathleen Burlew, et al.
Addiction (Abingdon, England)|February 26, 2005
Nefazodone treatment of cocaine dependence with comorbid depressive symptomsDomenic A Ciraulo, Clifford Knapp, John Rotrosen, et al.
Journal of Addiction Medicine|August 12, 2022
Commentary on Ajazi et al (2021) Re-analysis of the X:BOT TrialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
Addiction (Abingdon, England)|February 26, 2005
A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependenceMalcolm S Reid, Paul Casadonte, Sherryl Baker, et al.
Journal of Substance Abuse Treatment|June 30, 2022
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomesAmanda M Bunting, Noa Krawczyk, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|May 18, 2026
A Comparison of Neuropsychological Functioning Between Patients With Opioid Use Disorder Treated With Extended-Release Naltrexone or Buprenorphine-NaloxoneFelipe Castillo, Aimee N C Campbell, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|February 18, 2010
Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment ProgramsLawrence S Brown, Steven Kritz, Adashima Muhammad, et al.
Journal of Substance Abuse Treatment|June 12, 2021
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials NetworkLaTrice Montgomery, Theresa Winhusen, Jennifer Scodes, et al.
Journal of Substance Abuse Treatment|November 1, 2011
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United StatesEdmund J Bini, Steven Kritz, Lawrence S Brown, et al.
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvementMalcolm S Reid, Huiping Jiang, Bryan Fallon, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
Addictive Behaviors|July 4, 2020
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adultsAngela M Haeny, LaTrice Montgomery, A Kathleen Burlew, et al.
Addiction (Abingdon, England)|February 26, 2005
Nefazodone treatment of cocaine dependence with comorbid depressive symptomsDomenic A Ciraulo, Clifford Knapp, John Rotrosen, et al.
Journal of Addiction Medicine|August 12, 2022
Commentary on Ajazi et al (2021) Re-analysis of the X:BOT TrialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
Addiction (Abingdon, England)|February 26, 2005
A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependenceMalcolm S Reid, Paul Casadonte, Sherryl Baker, et al.
Journal of Substance Abuse Treatment|June 30, 2022
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomesAmanda M Bunting, Noa Krawczyk, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|May 18, 2026
A Comparison of Neuropsychological Functioning Between Patients With Opioid Use Disorder Treated With Extended-Release Naltrexone or Buprenorphine-NaloxoneFelipe Castillo, Aimee N C Campbell, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|February 18, 2010
Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment ProgramsLawrence S Brown, Steven Kritz, Adashima Muhammad, et al.
Journal of Substance Abuse Treatment|June 12, 2021
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials NetworkLaTrice Montgomery, Theresa Winhusen, Jennifer Scodes, et al.
Journal of Substance Abuse Treatment|November 1, 2011
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United StatesEdmund J Bini, Steven Kritz, Lawrence S Brown, et al.
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvementMalcolm S Reid, Huiping Jiang, Bryan Fallon, et al.
Pageof 16